The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study

References

• Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779. doi:10.1056/NEJM200106073442307
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Escobar M, Sallah S. Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis. J Thromb Haemost. 2013;11(8):1449–1453. doi:10.1111/jth.12317
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801–1809. doi:10.1016/S0140-6736(03)13405-8
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–197. doi:10.1016/S0140-6736(15)01123-X
   PubMed Web of Science ®Google Scholar
• Ljung R. Aspects of prophylactic treatment of hemophilia. Thromb J. 2016;14(Suppl 1):30. doi:10.1186/s12959-016-0103-3
   PubMedGoogle Scholar
• Kempton CL. Prophylaxis in hemophilia: how much is enough? Blood. 2021;137(13):1709–1711. doi:10.1182/blood.2020009603
   PubMed Web of Science ®Google Scholar
• Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447–1456. doi:10.1016/S0140-6736(11)61139-2
   PubMed Web of Science ®Google Scholar
• Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia. 2006;12(Suppl 3):117–121. doi:10.1111/j.1365-2516.2006.01268.x
   PubMed Web of Science ®Google Scholar
• Klamroth R, Kurnik K, Wenning S, et al. Pharmacokinetic-guided prophylaxis with rurioctocog alfa pegol improves bleeding rates over standard prophylaxis: real-world observational data from the AHEAD German study. Blood. 2021;138(Suppl 1):318. doi:10.1182/blood-2021-146162
   PubMed Web of Science ®Google Scholar
• Iorio A. Using pharmacokinetics to individualize hemophilia therapy. Hematology Am Soc Hematol Educ Program. 2017;2017(1):595–604. doi:10.1182/asheducation-2017.1.595
   PubMed Web of Science ®Google Scholar
• Croteau SE, Wheeler AP, Khan O, et al. Pharmacokinetic-tailored approach to hemophilia prophylaxis: medical decision making and outcomes. Res Pract Thromb Haemost. 2020;4(2):326–333. doi:10.1002/rth2.12305
   PubMed Web of Science ®Google Scholar
• Hazendonk H, van Moort I, Mathôt RAA, et al. OPTI-CLOT study group. Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play? Blood Rev. 2018;32(4):265–271. doi:10.1016/j.blre.2018.01.001
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang Q, Zheng L, et al. Efficacy of individualized preventive treatment of patients with severe hemophilia A guided by multiple clinical parameters and pharmacokinetics. Acta Haematol. 2021;145:354–361. doi:10.1159/000521360
   PubMed Web of Science ®Google Scholar
• Hermans C, Dolan G. Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review. Ther Adv Hematol. 2020;11:204062072096688. doi:10.1177/2040620720966888
   Web of Science ®Google Scholar
• Lissitchkov T, Rusen L, Georgiev P, et al. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia. 2017;23(5):697–704. doi:10.1111/hae.13251
   PubMed Web of Science ®Google Scholar
• Pasca S, Milan M, Sarolo L, Zanon E. PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. Thromb Res. 2017;157:58–63. doi:10.1016/j.thromres.2017.07.003
   PubMed Web of Science ®Google Scholar
• Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. Blood Coagul Fibrinolysis. 2017;28(6):425–430. doi:10.1097/MBC.0000000000000610
   PubMed Web of Science ®Google Scholar
• Chowdary P, Fischer K, Collins PW, et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis. Thromb Haemost. 2020;120(5):728–736. doi:10.1055/s-0040-1709519
   PubMed Web of Science ®Google Scholar
• Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8(2):269–275. doi:10.1111/j.1538-7836.2009.03703.x
   PubMed Web of Science ®Google Scholar
• Goedhart TMHJ, Bukkems LH, Zwaan CM, et al. Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice. Blood Adv. 2021;5(20):4314–4325. doi:10.1182/bloodadvances.2021005096
   PubMed Web of Science ®Google Scholar
• Solms A, Iorio A, Ahsman MJ, et al. Favorable pharmacokinetic characteristics of extended-half-life recombinant factor VIII BAY 94-9027 enable robust individual profiling using a population pharmacokinetic approach. Clin Pharmacokinet. 2020;59(5):605–616. doi:10.1007/s40262-019-00832-7
   PubMed Web of Science ®Google Scholar
• Mingot-Castellano ME, Parra R, Núñez R, Martorell M. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT®. Haemophilia. 2018;24(5):e338–e343. doi:10.1111/hae.13540
   PubMed Web of Science ®Google Scholar
• Klamroth R, Windyga J, Radulescu V, et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2021;137(13):1818–1827. doi:10.1182/blood.2020005673
   PubMed Web of Science ®Google Scholar
• O’Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106. doi:10.1186/s13023-017-0660-y
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Subcommittee on Factor VIII, Factor IX and rare coagulation disorders of the scientific and standardization committee of the international society on thrombosis and hemostasis. definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939. doi:10.1111/jth.12672
   PubMed Web of Science ®Google Scholar
• O’Hara J, Khair K, McLaughlin P, et al. “Problem Joint” a more patient relevant definition for joint morbidity in haemophilia. Haemophilia. 2019;25(S1):P154. doi:10.1111/hae.13666
   PubMedGoogle Scholar